Your browser doesn't support javascript.
loading
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.
Eriksson, Carl; Rundquist, Sara; Lykiardopoulos, Vyron; Udumyan, Ruzan; Karlén, Per; Grip, Olof; Söderman, Charlotte; Almer, Sven; Hertervig, Erik; Marsal, Jan; Gunnarsson, Jenny; Malmgren, Carolina; Delin, Jenny; Strid, Hans; Sjöberg, Mats; Öberg, David; Bergemalm, Daniel; Hjortswang, Henrik; Halfvarson, Jonas.
Afiliación
  • Eriksson C; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Södra Grev Rosengatan, SE-70182 Örebro, Sweden.
  • Rundquist S; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Lykiardopoulos V; Department of Gastroenterology and Hepatology, Linköping University, Linköping, Sweden.
  • Udumyan R; Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.
  • Karlén P; Department of Internal Medicine, Danderyd Hospital, Stockholm, Sweden.
  • Grip O; Department of Gastroenterology, Skåne University Hospital, Malmö, Sweden.
  • Söderman C; Department of Internal Medicine, St Göran Hospital, Stockholm, Sweden.
  • Almer S; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Hertervig E; Department of Gastroenterology, Skåne University Hospital, Lund, Sweden.
  • Marsal J; Department of Gastroenterology, Skåne University Hospital, Lund, Sweden.
  • Gunnarsson J; Department of Internal Medicine, Kungälv Hospital, Kungälv, Sweden.
  • Malmgren C; Takeda Pharma AB, Stockholm, Sweden.
  • Delin J; Department of Gastroenterology, Ersta Hospital, Stockholm, Sweden.
  • Strid H; Department of Internal Medicine, Södra Älvsborgs Hospital, Borås, Sweden.
  • Sjöberg M; Department of Internal Medicine, Skaraborgs Hospital, Lidköping, Sweden.
  • Öberg D; Department of Internal Medicine, Sunderby Hospital, Sunderbyn, Sweden.
  • Bergemalm D; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Hjortswang H; Department of Gastroenterology and Hepatology, Linköping University, Linköping, Sweden.
  • Halfvarson J; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Therap Adv Gastroenterol ; 14: 17562848211023386, 2021.
Article en En | MEDLINE | ID: mdl-34276808
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Therap Adv Gastroenterol Año: 2021 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Therap Adv Gastroenterol Año: 2021 Tipo del documento: Article País de afiliación: Suecia